{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:10:10Z","timestamp":1794975010648,"version":"4.9.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20328 and W2412035"],"award-info":[{"award-number":["U22A20328 and W2412035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60927-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:08:05Z","timestamp":1751357285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Engineering STING Nanoadjuvants for spatiotemporally-tailored innate immunity stimulation and cancer vaccination therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Fangmin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0912-8372","authenticated-orcid":false,"given":"Zhixiong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3323-3092","authenticated-orcid":false,"given":"Mingyue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4981","authenticated-orcid":false,"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4391-2507","authenticated-orcid":false,"given":"Zhiai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-0880","authenticated-orcid":false,"given":"Haijun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"60927_CR1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"60927_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","volume":"29","author":"CS Shemesh","year":"2021","unstructured":"Shemesh, C. S. et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol. Ther. 29, 555\u2013570 (2021).","journal-title":"Mol. Ther."},{"key":"60927_CR3","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy. Science 359, 1355\u20131360 (2018).","journal-title":"Science"},{"key":"60927_CR4","doi-asserted-by":"crossref","unstructured":"Sayour, E. J., Boczkowski, D., Mitchell, D. A. & Nair, S. K. Cancer mRNA vaccines: clinical advances and future opportunities. Nat. Rev. Clin. Oncol. 21, 489\u2212500 (2024).","DOI":"10.1038\/s41571-024-00902-1"},{"key":"60927_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s43018-023-00588-x","volume":"4","author":"A Peri","year":"2023","unstructured":"Peri, A. et al. The landscape of T cell antigens for cancer immunotherapy. Nat. Cancer 4, 937\u2013954 (2023).","journal-title":"Nat. Cancer"},{"key":"60927_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct. Target Ther. 8, 450 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"60927_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu, A. et al. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct. Target Ther. 9, 68 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"60927_CR8","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson, N. & Ablasser, A. The cGAS-STING pathway and cancer. Nat. Cancer 3, 1452\u20131463 (2022).","journal-title":"Nat. Cancer"},{"key":"60927_CR9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen, Q., Sun, L. & Chen, Z. J. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 17, 1142\u20131149 (2016).","journal-title":"Nat. Immunol."},{"key":"60927_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41573-019-0043-2","volume":"18","author":"C Vanpouille-Box","year":"2019","unstructured":"Vanpouille-Box, C., Hoffmann, J. A. & Galluzzi, L. Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles. Nat. Rev. Drug Discov. 18, 845\u2013867 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"60927_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41577-021-00577-0","volume":"22","author":"NA Lind","year":"2022","unstructured":"Lind, N. A., Rael, V. E., Pestal, K., Liu, B. & Barton, G. M. Regulation of the nucleic acid-sensing Toll-like receptors. Nat. Rev. Immunol. 22, 224\u2013235 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"60927_CR12","doi-asserted-by":"crossref","unstructured":"Chen, F. et al. Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer. Adv. Mater. 35, e2209910 (2022).","DOI":"10.1002\/adma.202209910"},{"key":"60927_CR13","doi-asserted-by":"publisher","first-page":"120709","DOI":"10.1016\/j.biomaterials.2021.120709","volume":"270","author":"F Chen","year":"2021","unstructured":"Chen, F. et al. Nanobiomaterial-based vaccination immunotherapy of cancer. Biomaterials 270, 120709 (2021).","journal-title":"Biomaterials"},{"key":"60927_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","volume":"14","author":"D Shae","year":"2019","unstructured":"Shae, D. et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat. Nanotechnol. 14, 269\u2013278 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"60927_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41587-019-0390-x","volume":"38","author":"GM Lynn","year":"2020","unstructured":"Lynn, G. M. et al. Peptide-TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat. Biotechnol. 38, 320\u2013332 (2020).","journal-title":"Nat. Biotechnol."},{"key":"60927_CR16","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s41565-022-01225-x","volume":"17","author":"K Yang","year":"2022","unstructured":"Yang, K. et al. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration. Nat. Nanotechnol. 17, 1322\u20131331 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"60927_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","volume":"16","author":"R Kuai","year":"2017","unstructured":"Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489\u2013496 (2017).","journal-title":"Nat. Mater."},{"key":"60927_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2214278119","volume":"119","author":"YT Wu","year":"2022","unstructured":"Wu, Y. T. et al. Tumor-targeted delivery of a STING agonist improvescancer immunotherapy. Proc. Natl. Acad. Sci. USA 119, e2214278119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60927_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06073-8","volume":"14","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway. Cell Death Dis. 14, 550 (2023).","journal-title":"Cell Death Dis."},{"key":"60927_CR20","doi-asserted-by":"publisher","first-page":"10715","DOI":"10.1021\/acs.jmedchem.3c00907","volume":"66","author":"JR Duvall","year":"2023","unstructured":"Duvall, J. R. et al. Discovery and optimization of a STING agonist platform for application in antibody drug conjugates. J. Med Chem. 66, 10715\u201310733 (2023).","journal-title":"J. Med Chem."},{"key":"60927_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41565-020-00781-4","volume":"15","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat. Nanotechnol. 15, 1043\u20131052 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"60927_CR22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nnano.2017.52","volume":"12","author":"M Luo","year":"2017","unstructured":"Luo, M. et al. A STING-activating nanovaccine for cancer immunotherapy. Nat. Nanotechnol. 12, 648\u2013654 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"60927_CR23","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41565-020-00782-3","volume":"15","author":"N Gong","year":"2020","unstructured":"Gong, N. et al. Proton-driven transformable nanovaccine for cancer immunotherapy. Nat. Nanotechnol. 15, 1053\u20131064 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"60927_CR24","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1039\/D2CS00647B","volume":"52","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Yang, B., Ni, Q. & Chen, X. Materials engineering strategies for cancer vaccine adjuvant development. Chem. Soc. Rev. 52, 2886\u20132910 (2023).","journal-title":"Chem. Soc. Rev."},{"key":"60927_CR25","doi-asserted-by":"publisher","first-page":"113927","DOI":"10.1016\/j.addr.2021.113927","volume":"177","author":"T Ye","year":"2021","unstructured":"Ye, T., Li, F., Ma, G. & Wei, W. Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors. Adv. Drug Deliv. Rev. 177, 113927 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"60927_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nri.2017.89","volume":"18","author":"J Weiden","year":"2018","unstructured":"Weiden, J., Tel, J. & Figdor, C. G. Synthetic immune niches for cancer immunotherapy. Nat. Rev. Immunol. 18, 212\u2013219 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"60927_CR27","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1021\/acs.accounts.0c00337","volume":"53","author":"SN Lee","year":"2020","unstructured":"Lee, S. N., Jin, S. M., Shin, H. S. & Lim, Y. T. Chemical strategies to enhance the therapeutic efficacy of toll-like receptor agonist based cancer immunotherapy. Acc. Chem. Res 53, 2081\u20132093 (2020).","journal-title":"Acc. Chem. Res"},{"key":"60927_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.it.2007.03.008","volume":"28","author":"A Macagno","year":"2007","unstructured":"Macagno, A., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol. 28, 227\u2013233 (2007).","journal-title":"Trends Immunol."},{"key":"60927_CR29","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/ni1223","volume":"6","author":"G Napolitani","year":"2005","unstructured":"Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. & Lanzavecchia, A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6, 769\u2013776 (2005).","journal-title":"Nat. Immunol."},{"key":"60927_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41565-022-01296-w","volume":"18","author":"SM Jin","year":"2023","unstructured":"Jin, S. M. et al. A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion. Nat. Nanotechnol. 18, 390\u2013402 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"60927_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","volume":"23","author":"C Glorieux","year":"2024","unstructured":"Glorieux, C., Liu, S., Trachootham, D. & Huang, P. Targeting ROS in cancer: rationale and strategies. Nat. Rev. Drug Discov. 23, 583\u2013606 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"60927_CR32","doi-asserted-by":"publisher","first-page":"eadl0479","DOI":"10.1126\/sciadv.adl0479","volume":"10","author":"X Li","year":"2024","unstructured":"Li, X. et al. Precise modulation and use of reactive oxygen species for immunotherapy. Sci. Adv. 10, eadl0479 (2024).","journal-title":"Sci. Adv."},{"key":"60927_CR33","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.molcel.2020.12.024","volume":"81","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. SENP3 senses oxidative stress to facilitate STING-dependent dendritic cell antitumor function. Mol. Cell 81, 940\u2013952 e945 (2021).","journal-title":"Mol. Cell"},{"key":"60927_CR34","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527\u20131538 (2015).","journal-title":"Cell"},{"key":"60927_CR35","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41551-021-00781-2","volume":"5","author":"IC Miller","year":"2021","unstructured":"Miller, I. C. et al. Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nat. Biomed. Eng. 5, 1348\u20131359 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"60927_CR36","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41551-021-00779-w","volume":"5","author":"Y Wu","year":"2021","unstructured":"Wu, Y. et al. Control of the activity of CAR-T cells within tumours via focused ultrasound. Nat. Biomed. Eng. 5, 1336\u20131347 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"60927_CR37","doi-asserted-by":"crossref","unstructured":"Wang, D. et al. Engineering nanoparticles to locally activate T cells in the tumor microenvironment. Sci. Immunol. 4, eaau6584 (2019).","DOI":"10.1126\/sciimmunol.aau6584"},{"key":"60927_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37225-1","volume":"14","author":"X Ma","year":"2023","unstructured":"Ma, X. et al. Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field. Nat. Commun. 14, 1606 (2023).","journal-title":"Nat. Commun."},{"key":"60927_CR39","doi-asserted-by":"publisher","first-page":"e1902960","DOI":"10.1002\/adma.201902960","volume":"31","author":"B Feng","year":"2019","unstructured":"Feng, B. et al. Self-amplified drug delivery with light-inducible nanocargoes to enhance cancer immunotherapy. Adv. Mater. 31, e1902960 (2019).","journal-title":"Adv. Mater."},{"key":"60927_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42509-7","volume":"14","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Nanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity. Nat. Commun. 14, 6973 (2023).","journal-title":"Nat. Commun."},{"key":"60927_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun, S. C. Non-canonical NF-kappaB signaling pathway. Cell Res 21, 71\u201385 (2011).","journal-title":"Cell Res"},{"key":"60927_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cr.2010.178","volume":"21","author":"MJ Morgan","year":"2011","unstructured":"Morgan, M. J. & Liu, Z. G. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 21, 103\u2013115 (2011).","journal-title":"Cell Res"},{"key":"60927_CR43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nri.2017.21","volume":"17","author":"AP West","year":"2017","unstructured":"West, A. P. & Shadel, G. S. Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat. Rev. Immunol. 17, 363\u2013375 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"60927_CR44","doi-asserted-by":"publisher","first-page":"e49799","DOI":"10.15252\/embr.201949799","volume":"21","author":"JS Riley","year":"2020","unstructured":"Riley, J. S. & Tait, S. W. Mitochondrial DNA in inflammation and immunity. EMBO Rep. 21, e49799 (2020).","journal-title":"EMBO Rep."},{"key":"60927_CR45","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.tcb.2022.11.001","volume":"33","author":"C Chen","year":"2023","unstructured":"Chen, C. & Xu, P. Cellular functions of cGAS-STING signaling. Trends Cell Biol. 33, 630\u2013648 (2023).","journal-title":"Trends Cell Biol."},{"key":"60927_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112185","volume":"42","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. NF-kappaB activation enhances STING signaling by altering microtubule-mediated STING trafficking. Cell Rep. 42, 112185 (2023).","journal-title":"Cell Rep."},{"key":"60927_CR47","doi-asserted-by":"publisher","first-page":"113914","DOI":"10.1016\/j.addr.2021.113914","volume":"179","author":"Y Ding","year":"2021","unstructured":"Ding, Y., Li, Z., Jaklenec, A. & Hu, Q. Vaccine delivery systems toward lymph nodes. Adv. Drug Deliv. Rev. 179, 113914 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"60927_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.addr.2020.08.009","volume":"161-162","author":"R Tian","year":"2020","unstructured":"Tian, R., Ke, C., Rao, L., Lau, J. & Chen, X. Multimodal stratified imaging of nanovaccines in lymph nodes for improving cancer immunotherapy. Adv. Drug Deliv. Rev. 161-162, 145\u2013160 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"60927_CR49","doi-asserted-by":"publisher","first-page":"eaba4024","DOI":"10.1126\/sciadv.aba4024","volume":"6","author":"L Fang","year":"2020","unstructured":"Fang, L. et al. Engineering autologous tumor cell vaccine to locally mobilize antitumor immunity in tumor surgical bed. Sci. Adv. 6, eaba4024 (2020).","journal-title":"Sci. Adv."},{"key":"60927_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.biomaterials.2018.08.016","volume":"182","author":"LJ Ochyl","year":"2018","unstructured":"Ochyl, L. J. et al. PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy. Biomaterials 182, 157\u2013166 (2018).","journal-title":"Biomaterials"},{"key":"60927_CR51","doi-asserted-by":"crossref","unstructured":"Chen, L. et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci. Transl. Med. 13, eabc2816 (2021).","DOI":"10.1126\/scitranslmed.abc2816"},{"key":"60927_CR52","doi-asserted-by":"publisher","first-page":"eadk7955","DOI":"10.1126\/sciadv.adk7955","volume":"10","author":"G Qiao","year":"2024","unstructured":"Qiao, G. et al. Surgical tumor-derived nanoplatform targets tumor-associated macrophage for personalized postsurgical cancer immunotherapy. Sci. Adv. 10, eadk7955 (2024).","journal-title":"Sci. Adv."},{"key":"60927_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91\u2013113 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"60927_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro, A. C., Lin, N. U. & Polyak, K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 9, 176\u2013198 (2019).","journal-title":"Cancer Discov."},{"key":"60927_CR55","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang, J. D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16, 589\u2013604 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"60927_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01467-8","volume":"20","author":"Z Cai","year":"2021","unstructured":"Cai, Z. et al. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. Mol. Cancer 20, 164 (2021).","journal-title":"Mol. Cancer"},{"key":"60927_CR57","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro, B., Sarobe, P., Hervas-Stubbs, S. & Melero, I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 525\u2013543 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"60927_CR58","doi-asserted-by":"crossref","unstructured":"Chen, H. et al. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8(+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models. J. Immunother. Cancer 10, e004389 (2022).","DOI":"10.1136\/jitc-2021-004389"},{"key":"60927_CR59","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.tips.2022.08.006","volume":"43","author":"J Guo","year":"2022","unstructured":"Guo, J. & Huang, L. Nanodelivery of cGAS-STING activators for tumor immunotherapy. Trends Pharmacol. Sci. 43, 957\u2013972 (2022).","journal-title":"Trends Pharmacol. Sci."},{"key":"60927_CR60","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/s41551-020-0597-7","volume":"4","author":"F Wang","year":"2020","unstructured":"Wang, F. et al. Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel. Nat. Biomed. Eng. 4, 1090\u20131101 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"60927_CR61","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41551-020-00675-9","volume":"5","author":"S Li","year":"2021","unstructured":"Li, S. et al. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat. Biomed. Eng. 5, 455\u2013466 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"60927_CR62","doi-asserted-by":"publisher","first-page":"e2000064","DOI":"10.1002\/adhm.202000064","volume":"9","author":"M Zhou","year":"2020","unstructured":"Zhou, M. et al. Multifunctional STING-activating Mn(3) O(4) @Au-dsDNA\/DOX nanoparticle for antitumor immunotherapy. Adv. Health. Mater. 9, e2000064 (2020).","journal-title":"Adv. Health. Mater."},{"key":"60927_CR63","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41565-021-00962-9","volume":"16","author":"X Sun","year":"2021","unstructured":"Sun, X. et al. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat. Nanotechnol. 16, 1260\u20131270 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"60927_CR64","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41563-022-01251-z","volume":"21","author":"EL Dane","year":"2022","unstructured":"Dane, E. L. et al. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nat. Mater. 21, 710\u2013720 (2022).","journal-title":"Nat. Mater."},{"key":"60927_CR65","doi-asserted-by":"publisher","first-page":"eabc3646","DOI":"10.1126\/sciadv.abc3646","volume":"6","author":"J Liang","year":"2020","unstructured":"Liang, J. et al. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity. Sci. Adv. 6, eabc3646 (2020).","journal-title":"Sci. Adv."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60927-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60927-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60927-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:02:34Z","timestamp":1751360554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60927-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60927"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60927-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5773"}}